Palbociclib

Most common adverse reactions include mouth sore, low red blood cells count, nosebleeds, dizziness, tiredness, weakness, hair thinning, diarrhea and nausea.

Serious side effects of palbociclib include fertility problems in males, bruising and shortness of breath.

• Palbociclib 125 mg may cause fetal harm whenever administered to pregnant women.
• Patients taking Palbace 125 mg should have their complete blood counts monitored at the beginning of each cycle also on day 15 of an initial couple of cycles and as clinically indicated.
• Should be interrupt or permanently disclose the dose of Palbace 100 mg in the patients with worsening respiratory symptoms.

• Co-administration of a strong CYP3A inhibitor increased the plasma exposure of palbociclib in healthy subjects by 87%. Avoid concomitant administration of strong CYP3A inhibitors (e.g., lopinavir/ritonavir, clarithromycin, itraconazole, indinavir, ketoconazole, nelfinavir, posaconazole, nefazodone, ritonavir, saquinavir, telaprevir, voriconazole, and telithromycin.
• Avoid grapefruit or grapefruit juice while on palbociclib treatment. In case coadministration of palbociclib with a strong CYP3A inhibitor cannot be avoided, reduce the dosage of palbociclib.
• Coadministration of a strong CYP3A inducer reduced the plasma exposure of palbociclib in healthy subjects by 85 percent. Avoid concomitant administration of strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine, enzalutamide, and St John’s Wort).
• The dosage of sensitive CYP3A4 substrates with narrow therapeutic indices may be required to be reduced when administered concurrently with palbociclib.